Pioneering a Transformative Era in Autoimmunity through B-Cell Depletion & Advancing Precision Therapies to Reprogram the Immune System to Move Beyond Standard Immunosuppression
The era of blanket immunosuppression is ending. A new chapter in autoimmune therapy is unfolding, one where precision replaces broad suppression, and immune resetting takes centre stage.
B-cell depletion therapies have paved the way, but the question remains: what’s next?
Innovations such as cell therapy, T-cell engagers, bispecifics, and next-generation monoclonal antibodies are no longer distant possibilities, they’re here, poised to redefine treatment paradigms. What was once blue-sky thinking is now becoming a reality, fueled by major investments and strategic acquisitions like Kite Pharma’s move for Interius Biotherapeutics and AbbVie’s acquisition of Capstan. Rising interest in targets such as BCMA for lupus nephritis signals a seismic shift toward curative potential.
Harnessing this energy, the inaugural Immune Resetting: B-Cell Mediated & Beyond Summit launches at this pivotal moment, uniting biopharma leaders, academic KOLs, and immunology innovators to accelerate progress. From discovery through clinical application, this is your opportunity to benchmark strategies, build partnerships, and take actionable insights back to your programs.
Join 50+ experts to explore how targeted interventions can recalibrate the immune system, delivering durable, transformative therapies for lupus, systemic sclerosis, rheumatoid arthritis, multiple sclerosis, and beyond. The future of autoimmune care is being written and you should be a part of it.
I look forward to hearing and seeing the latest developments in immune resetting and meeting with a diverse group of researchers in this field. I am also excited to present Hinge’s GEM-DIMER molecule, HB2198, for depletion of CD19/CD20 expressing B cells.
Steve Chapin, Senior Director – Preclinical Development, Hinge Bio
I am interested to share our observations for B-cell depletion and reconstitution in Rese-cel treated individuals and hear what others have seen in their trials.
Jason Stadanlick, Principal Scientist, Cabaletta Bio
This is a rapidly evolving space, and the collaboration and information shared from companies was incredibly valuable at the TCEs for Autoimmune Disease Summit. I think we all believe we are competing but also each success will help the whole field out.
Tapan Maniar, Chief Medical Officer, Oblenio Bio
Explore the Full Event Guide
- 50+ Industry Attendees
- 18+ World-Class Speakers
- 5+ Modalities Covered
- 6+ Hours of Unrivaled Networking Opportunities
- 2 Deep-Dive Workshops
- The only industry forum dedicated to advancing curative therapies for autoimmune diseases through immune resetting
Attending Companies Include
Explore Related Events
Explore the Brand-New Agenda
Hear the latest industry breakthroughs in B-cell mechanistic understanding and gain exclusive modality and platform insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself as the go-to service provider of the rapidly progressing ‘Immune Resetting’ landscape to ensure your brand is at the heart of deals in this evolving space.
Join Biopharma Experts
Be part of the most critical conversations shaping the future of autoimmune therapy. Connect with like-minded experts across every stage of drug development, from discovery to clinical application, and dive into focused discussions on redefining immune reset.